Sekesis Biotech Co., Ltd. (Sekesis) has had its application for an initial public offering on the Shanghai Stock Exchange's STAR Market accepted. China Everbright Securities is serving as the sponsor for the offering, which aims to raise 635 million yuan. According to the prospectus, Sekesis focuses on the research, development, production, and sale of absorbable implantable medical devices. The company's primary products include absorbable dura sealant medical adhesive, absorbable vascular sealant medical adhesive, composite microporous polysaccharide hemostatic powder, and surgical anti-adhesion fluid. The absorbable dura sealant medical adhesive is the first innovative product successfully developed in its specific segment in China. Currently, the company holds approximately 91% of the domestic dura sealant adhesive market, maintaining the leading position. Its absorbable vascular sealant medical adhesive is the only domestically produced product in its segment, capturing about 70% of the domestic vascular sealant adhesive market and successfully achieving import substitution. This product is expected to further increase its market penetration. At the same time, the company's composite microporous polysaccharide hemostatic powder and surgical anti-adhesion fluid also hold significant positions in China. The hemostatic powder holds a 27.67% market share in the domestic micro-powder absorbable hemostatic material segment, ranking first in the sub-industry. The surgical anti-adhesion fluid holds a 20.53% share in the domestic surgical anti-adhesion material market, ranking second in the industry. As of the end of the reporting period, the company possessed 25 medical device products, with several key research and development pipelines progressing smoothly. Among these, three projects are in the registration review stage, three are in the clinical trial stage, and seven are in the process research and registration testing stage. The pipeline products cover globally high-growth sectors such as neurosurgery, orthopedics, and radiation oncology. The net proceeds from the offering, after deducting issuance expenses, will be allocated to specific projects. Financially, for the years 2023, 2024, and 2025, the company reported operating revenues of 379 million yuan, 331 million yuan, and 338 million yuan, respectively. Net profit for the same periods was approximately 153 million yuan, 161 million yuan, and 168 million yuan, respectively.